Massive study to reveal Real-World impact of popular obesity drugs
NCT ID NCT07640139
First seen Jun 16, 2026 · Last updated Jun 20, 2026 · Updated 1 time
Summary
This observational study will follow 125,000 adults with employer-based insurance to see how GLP-1 and GLP-1/GIP obesity medications (like Wegovy and Zepbound) affect weight, healthcare use, and costs. Researchers will compare those who take the drugs to those who don't, using existing medical and pharmacy claims data. The goal is to understand the real-world benefits and economic impact of these treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Indiana University
Indianapolis, Indiana, 46203, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Incretin-based therapies (GLP-1 and GLP-1/GIP drugs like Zepbound, Wegovy, Saxenda)
What this could lead to
If successful, this study could show whether these medications reduce obesity-related health problems and lower medical costs in a real-world setting.
What could go wrong
This is an observational study, not a controlled trial, so it can only show associations, not cause and effect. Results may not apply to people without employer insurance.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.